Latest papers

Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.

Synthesis, characterization, and cyclic stress-influenced degradation of a poly(ethylene glycol)-based poly(beta-amino ester).

Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.

Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine.

Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Chemical modification of Posidonia with cyclic anhydrides: effect on thermal stability.

Occurrence and treatment of ADHD in adults.

Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study.

Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY.

The Use of the Intention-to-Treat Principle in Nursing Clinical Trials

Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.

Sensitivity of parent reports in the MTA.

The MTA at 8.

Pharmacologic mood destabilization: case vignettes.

Treatment of aggressive ADHD in children and adolescents: conceptualization and treatment of comorbid behavior disorders.

The MTA at 8.

Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.

1,3-Diazido-2-(azidomethyl)-2-propylammonium Salts